No Data
ZHAOKE OPHTH-B (6622.HK): The registration application for NVK002 has been formally accepted, further enhancing growth certainty.
Nowadays, the issue of myopia in children is becoming increasingly serious, and how to prevent and delay the development of myopia in children has become a focus of widespread attention among parents. As a result, various treatment methods have emerged in the market, and related discussions have become more intense. From traditional glasses to modern orthokeratology lenses and defocus lenses, as well as drug treatments, parents are urgently seeking suitable solutions for their children, hoping to find the safest and most effective way to delay myopia as soon as possible. Recently, Zhaoke Ophthalmology announced the simple new drug application for NVK002 (0.01% low-dose atropine), a medication used to control the progression of myopia in children, which has been officially accepted by the National Medical Products Administration. This means that
Selected Announcements | Alibaba's buyback plan still has a remaining amount of 20.7 billion USD; GTJA plans to conduct a stock swap to absorb and merge HAITONG SEC and will send a proposal to the meeting for fundraising support.
In 2024, Qinhuangdao Port's total throughput reached 0.414 billion tons, a year-on-year increase of 5.66%; ZHAOKE OPHTH-B: The National Medical Products Administration accepted the simplified new drug application for NVK002, used to treat worsening myopia in children.
Zhitong Hong Kong stocks early news | China Securities Regulatory Commission: "The rumor that all Bearish will be released before January 15 is false". The S&P and Nasdaq recorded five consecutive declines.
China Securities Regulatory Commission: "Releasing all Bearish before January 15" and "Insurance companies large redemptions of public Funds" are both rumors.
Express News | Zhaoke Ophthalmology - Nmpa Acceptance of Abbreviated New Drug- Application for Nvk002 for Treatment of- Myopia Progression in Children
Hong Kong stocks movement | ZHAOKE OPHTH-B (06622) once rose more than 8% as the drug for treating wet age-related macular degeneration reached the primary endpoint in its Phase III clinical trial.
ZHAOKE OPHTH-B (06622) once rose over 8%, as of the time of writing, it increased by 5.83%, priced at 1.27 Hong Kong dollars, with a transaction amount of 0.8308 million Hong Kong dollars.
Zhao Ke Ophthalmology (06622): TAB014 related clinical trials have yielded positive results.
Kingwo Financial News | Zhaoke Ophthalmology (06622) announced that TAB014 (one of the company's core candidate drugs) has positive topline results from the Phase III clinical trial for the treatment of wet (neovascular) age-related macular degeneration (“wAMD”). This clinical trial successfully achieved the primary endpoint and key secondary endpoints. The Phase III clinical trial of TAB014 is a randomized, double-blind, and non-inferiority study, with the main objective of assessing the best corrected visual acuity (BCVA) at week 52 for the group receiving TAB014 treatment compared to the group receiving Lucentis treatment at baseline.
